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Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most 
widely used medications for the treatment of osteoarthritis (OA) and rheumatoid 
arthritis (RA). Unfortunately, it has been well documented that NSAIDs cause a 
wide spectrum of minor gastrointestinal (GI) side effects of dyspepsia and 
damage to the GI mucosa. More importantly, NSAIDs can cause serious GI 
events such as obstruction, bleeding, perforation and even death. Among the 
Hong Kong Chinese population aged 70 and above, arthritis was projected to be 
the chronic disease afflicting about 30% of the elderly population and peptic 
ulcer disease was predicted to become the fourth chronic disease afflicting about 
13.2% of the geriatric population [Woo et al 1997]. Therefore, the widespread 
use of NSAIDs can be translated into an important health problem. Treatment 
and prevention of GI side effects or even complications will significantly 
increase the cost of N S A I D therapies. Given the economic toll of arthritis, the 
high treatment cost and the chronic nature of the disease, economic evaluations 
of the benefit of various agents used to treat the disease could be useful for 
determining optimal resource allocation. 
The present study represents one of the first local studies relating to cost of 
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illness of upper GI events associated with the use of non-selective 
anti-inflammatory drugs. In addition, it is possible to evaluate the impact of 
introducing selective cyclooxygenase (C0X)-2 inhibitors, using data from 
clinical practice in local hospital settings and from large randomized clinical 
trials. 
Method 
Cost of illness of upper GI events 
367 patients who presented to the Accident and Emergency (A&E) 
Department with complaints of GI symptoms and received treatment for upper 
GI events in the United Christian Hospital (UCH) from January 1, 1999 to 
March 31，1999 were recruited. Data were collected through retrospective 
patient medical record review. Resources required for the treatment and follow 
up of GI events include medications, hospitalizations, clinic visits, A & E visits, 
lab tests, oesophagogastroduodenoscopy (OGD) and GI procedures. 
Cost analysis of selective COX-2 inhibitor versus non-selective N S A I D plus 
gastroprotective agent 
(a) Local randomized clinical trial 
The medical records of 287 arthritis patients with a history of ulcer 
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bleeding who had previously participated in a randomized clinical study of 
celecoxib 200mg twice daily and extended release diclofenac 75mg twice daily 
with omeprazole 20mg daily for 6 months were reviewed retrospectively. 
(b) Large randomized clinical trial 
Analysis was conducted from using incidence of GI events rates from the 
Vioxx Gastrointestinal Outcomes Research (VIGOR) trial. A total of 8,076 
patients with rheumatoid arthritis, were randomized to receive either 50mg/day 
rofecoxib, or 500mg naproxen twice daily for a median of nine months. Local 
cost of COX-2 inhibitor and non-selective NSAIDs were applied to the results 
of the V I G O R trial. 
Results 
Cost of illness of upper GI events 
The estimated total direct medical cost of upper GI events from Jan to 
31 St Mar 1999 was $12,412,796. Based on the three months results, the 
projected cost of upper GI events in U C H year 1999 was estimated to be 
$49,651,184. 
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Cost analysis of selective C O X - 2 inhibitor versus non-selective N S A I D plus 
gastroprotective agent 
(a) Local randomized clinical trial 
Median total direct cost per patient in the celecoxib group was significantly 
lower than in the diclofenac plus omeprazole group by 11% from $9,714 (range 
$9,714-$89，770) to $10,915 (range $10,915-$57,899; pO.OOOl). The median 
direct medical cost for routine management in the celecoxib group was also 
significantly lower than in the diclofenac plus omeprazole group by 11% from 
$9,714 (range $6,946-$26,179) to $10,915 (range $10,915-$28,048; pO.OOOl). 
For patients who experienced recurrent ulcer bleeding, the median cost for the 
management of recurrent bleeding in the celecoxib group showed a significant 
increase than in the diclofenac plus omeprazole group from $23,210 (range 
$12,318-$65,834) to $8,466 (range $572-$29,851; p=0.036). 
(b) Large randomized clinical trial 
For a cohort of 125 R A patients, it would cost $136,875 more H K D to 
provide celecoxib compared with diclofenac in order to prevent one GI event at 
a cost of $32,200 H K D . 
xi 
Conclusion 
A considerable amount of money is spent to manage upper GI adverse 
events associated with the use of non-selective non-steroidal anti-inflammatory 
drugs in Hong Kong. Celecoxib therapy appears to cost less compared to 
diclofenac plus omeprazole for the treatment of arthritis patients with a high risk 
of GI bleeding in local hospital setting and was higher with general R A patients 
from a large randomized clinical trial. Therefore, a large randomized local 
clinical trial is needed to better examine the cost effectiveness of selective 
COX-2 inhibitors and non-selective NSAIDs for treatment as well as prevention 



































中戶斤做的 celecoxib 200mg twice daily 禾口 extended release diclofenac 75mg twice 





























List of Abbreviations 
A C R American College of Rheumatology 
A P C Adenoma Prevention with Celecoxib 
A P P R O V e Adenomatous Polyp Prevention On Vioxx 
A R A M I S Arthritis, Rheumatism, and Aging Medical Information System 
A & E Accident and Emergency 
C D D H Corporate Drug Dispensing History 
C L A S S Celecoxib Long term Arthritis Safety Study 
C O X Cyclooxygenase 
F D A Food and Drug Administration 
GI Gastrointestinal 
H A Hospital Authority 
M U C O S A Misoprostol Ulcer Complication Outcomes Safety Assessment 
NICE National Institute for Clinical Excellence 
NSAIDs Non-steroidal anti-inflammatory drugs 
O A Osteoarthritis 
O G D Oesophagogastroduodenoscopy 
PPI Proton pump inhibitor 
R A Rheumatoid arthritis 
xvii 
T A R G E T Therapeutic Arthritis Research and Gastrointestinal Event Trial 
T E Thromboembolic 
U C H United Christian Hospital 
U K United Kingdom 
U S United States 
V I G O R Vioxx Gastrointestinal Outcomes Research 
xviii 
List of Tables 
Table 1 Nonpharmacologic therapy for patients with osteoarthritis 
Table 2 Pharmacologic therapy for patients with osteoarthritis 
Table 3 Risk factors for serious GI bleeding with N S A I D therapy 
Table 4 Cost of major health care resources items 
Table 5 Demographics characteristics of the patients 
Table 6 Distribution of upper GI complaints in U C H from Jan 1 to Mar 31 
1999 
Table 7 Partitioning of total direct medical costs of upper GI complaints in 
U C H Quarter 1999 
Table 8 Breakdown of health care resources used for treating of upper GI 
complaints in 广 Quarter 1999 in U C H 
Table 9 Average total direct medical costs of patients reported use of 
NSAID/aspirin in Quarter 1999 in U C H 
Table 10 Cost of major health care resources items 
Table 11 The baseline characteristic of the patients 
Table 12 Median total direct medical cost per patient of the celecoxib group 
and the diclofenac plus omeprazole group 
xix 
List of Figures 
Figure 1 Biosynthesis of prostaglandins through the cyclooxygenase pathways 
Figure 2 Selective COX-2 Inhibitors: Chemical Structures 
Figure 3 One-way sensitivity analysis of the expected median direct cost of 
the celecoxib group and the diclofenac plus omeprazole group 
using various cost of omeprazole (20mg) 
XX 
Chapter 1 Introduction 
1.1 The role of Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs, which provide effective analgesic, antipyretic and 
anti-inflammatory effects, are prescribed widely for the symptomatic relief of 
osteoarthritis (OA), rheumatoid arthritis (RA), acute musculoskeletal disorders, 
low back pain, acute gout, symptoms of the common cold and primary 
dysmenorrhoea. In the United Kingdom (UK), about 26 million prescriptions 
were written in each year [Haslock 1998]. In the United States (US), NSAIDs 
accounted for 3 % of the U S prescription drug market [Spiegel et al 2003]. It has 
been estimated that 13 million individuals regularly use NSAIDs [Lee et al 
1996]. Americans spent 4.5 billion dollars on NSAID prescriptions in 2000 
"Solomon et al 2003:. 
1.2. NSAID-induced gastrointestinal (GD toxicity 
Despite the clinical benefit ofNSAIDs through the inhibition of enzyme 
cyclooxygenase (COX), many of the unwanted side effects ofNSAIDs, 
including gastrointestinal mucosal damage, are induced by the inhibition of the 
same enzyme. Gastric mucosal damage resulting in outcomes ranging from 
non-specific dyspepsia to ulceration, upper gastrointestinal bleeding and death. 
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1.2.1 Pathogenesis of NSAID-induced GI toxicity 
NSAED-induced topical GI mucosal injuries have involved multiple 
mechanisms with both local and systemic effects. The systemic effects are 
mainly the results of inhibition of endogenous prostaglandin synthesis. 
Prostaglandin inhibition leads to decreases in epithelial mucus, secretion of 
bicarbonate, mucosal blood flow and epithelial proliferation. 
Prostaglandins are derived form arachidonic acid, which originates from 
cell-membrane phospholipids through the action of phospholipase A2. Two 
separate enzymatic pathways exist for the conversion of arachidonic acid to 
physiologically important metabolites. The cyclooxygenase pathway catalyzes 
the metabolism of arachidonic acid to prostaglandins. Cyclooxygenase initiates 
the formation of prostaglandins and thromboxane (Figure 1). Through a second 
pathway medicated by 5-lipoxygenase, arachidonic acid is converted to 
leukotrienes, which are potent mediators of the inflammatory response 
including bronchoconstriction, increased vascular permeability, leukocyte 
adhesion to vessel walls and edema. 
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Cyclooxygenase -1 Cyclooxgenase -2 
(Constitutive) (Inducible) 
I T 
Platelet aggregation Inflammation and pain 
Gastrointestinal integrity 
Renal function 
Two isoforms of C O X have been identified. COX-1 appears to exert 
diverse homeostatic, or function as a ‘housekeeping，enzyme. First, it protects 
the gastrointestinal mucosal lining and limit gastric acid secretion. Second, it 
regulates renal hemodynamics and water/electrolyte balance. Third, 
thromboxane A2 stimulates platelet aggregation and thus maintains normal 
hemostasis. 
O n the other hand, the expression of COX-2 can be induced by 
inflammatory stimuli. COX-2 metabolites are intimately involved in the 
production of pain and inflammatory. It has been suggested that the 
anti-inflammatory properties of NSAIDs are mediated through the inhibition of 
COX-2, whereas adverse effects, such as GI ulceration, occur as a result of 
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effects on the constitutively expressed COX-1 [Lee 1999，Wolfe et al 1999；. 
1.2.2 GI symptoms 
Ten to sixty percent of patients taking N S A I D s develop a gastrointestinal 
complaint. These problems include abdominal pain, heartburn, bloating and 
dyspepsia. Dyspepsia affects a large population. In a review article by Wolfe et 
al 1999, at least 10 to 2 0 % of patients have dyspepsia while taking N S A I D , 
although the prevalence range from 5 to 50 % . 
1.2.3 GI ulcers 
The majority of NSAID-induced ulcers are asymptomatic, often the initial 
symptom of an NSAID-induced ulcer is bleeding or perforation. W h e n an ulcer 
is suspected, endoscopy is performed for diagnosis. However, dyspeptic 
symptoms during N S A I D therapy are poorly correlated with the endoscopic 
appearance and severity of mucosal injury, since up to 4 0 % of patients with 
endoscopic evidence of erosive gastritis are asymptomatic and 5 0 % of patients 
with dyspepsia have normal appearing mucosa [Wolfe et al 1999]. In a study 
preformed by Larkai et al 1987, dyspeptic symptoms were present in 19% of 
R A patients receiving regular N S A E D therapy who had normal endoscopic 
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findings. Geis et al 1991 reported that the incidence of gastric ulcers was 14% 
and 9 % for duodenal ulcers due to chronic NSAIDs use. Armstrong and Blower 
1987 reported that the first sign of a peptic ulcer in 58% of patients taking 
NSAIDs was an acute life threatening complication. In a minority of cases, 
chronic ulcers cause life-threatening complications, including bleeding and 
perforation. 
1.2.4 GI complications 
Serious GI complications including ulceration, hemorrhage, and 
perforation can be life threatening in patients with regular use of NSAIDs. 
According to Arthritis, Rheumatism, and Aging Medical Information System 
(ARAMIS) data, 13 per 1000 patients per year with R A who take N S A I D for 
one year have a serious GI complication. A number of case control studies in the 
U S and U K have reported an association between ulcer related deaths and 
N S A I D use. N S A I D related GI complications are estimated to lead to 107,000 
hospitalizations and 16,500 deaths yearly in the U S [Wolfe et al 1999]. With 
chronic N S A I D use, the risk of an upper gastrointestinal bleeding episode is 1% 
to 4 % per year. The magnitude of the risk varies with the specific N S A I D being 
taken, medication doses, other medications being taken and patients' risk 
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factors. 
1.2.5 Risk factor for GI complications 
Regarding the morbidity and mortality associated with the toxicity of 
NSAIDs therapy, a number of studies have identified patients who are most 
likely to have NSAID-induced GI adverse events. Elderly aged 65 years and 
over, a history of peptic ulcer disease, the use of multiple NSAIDs or 
anticoagulants, concomitant use of corticosteroids and co-morbid medical 
conditions are factors enhanced the risks of GI toxicity of NSAIDs therapy 
[Altman et al 2000:. 
1.2.6 Ulcerogenictv of different NSAIDs in upper GI events 
It is clear that COX-1 inhibition plays a major role in developing ulcers 
and complications. Clinical studies have demonstrated that different NSAIDs 
carry different risks for producing serious GI complications. Griffin et al 1991 
computed the relative risks for the development of peptic ulcer disease for 
non-selective N S A I D by dose and reported that relative risks for the 
development of peptic ulcer among regular N S A I D user increased with 
increasing dose and ulcer formation with several NSAIDs reported from a low 
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relative risks of 2.3 for ibuprofen to a high of 8.7 for meclofenamate. In addition, 
Gabriel et al 1991 and Henry et al 1993 found the greatest risk for 
complications with piroxicam，with progressive lower risk ratio for 
indomethacin, aspirin, naproxen and ibuprofen. Although only a minority of 
patients taking NSAIDs develop serious complications, the widespread 
prescription and over the counter use of these drugs makes them a c o m m o n 
source of morbidity and mortality. 
1.3 Prevention of NSAID-induced GI toxicity 
The most obvious way of eliminating the risk of NSAID-induced GI 
toxicity is to avoid the use of these agents. Discontinuation o f N S A I D therapy 
allows restoration of the normal gastroprotective mechanisms and usually 
results in ulcer healing. The American College of Rheumatology (ACR) 
recommended nonpharmacologic modalities and drug therapy for the 
management of hip or knee osteoarthritis. It has been reported that drug therapy 
for pain management is most effective when combined with nonpharmacologic 
strategies. The A C R has recommended the use of paracetamol as first line 
pharmacological therapy for O A of hip or knee. Effective prophylaxis and 
treatment of NSAID-induced GI toxicity center on the use of H2-receptor 
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antagonists, misoprostol, proton pump inhibitor and selective COX-2 inhibitors. 
1.3.1 H^-receptor antagonists 
Conventional therapy with H2-receptor antagonists has been prescribed for 
the prevention of NSAID-induced ulcers. In a study reported by Ehsanullah et al 
1988, the incidence of duodenal ulcer after 8 weeks of treatment was significant 
lower in the ranitidine treated group compared with the placebo group. However, 
gastric ulceration was the same in both groups. In a study by Taha et al 1996, 
treatment with high dose famotidine (40mg twice daily) reduced the cumulative 
incidence of both gastric and duodenal ulcers in patients with arthritis receiving 
long term N S A I D therapy. 
1.3.2 Misoprostol 
Misoprostol has been extensively evaluated for its efficacy in preventing 
NSAID-induced GI damage. Raskin et al 1995 compared three regimes of 
misoprostol {lOOug twice daily, three times, or four times a day) and concluded 
that although lower dose of misoprostol are better tolerated, the drug needs to be 
taken at least three times a day to provide effective prophylaxis against 
NSAID-induced gastric ulcers. In a placebo-controlled study, misoprostol 
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prophylaxis significantly reduced the incidence of duodenal and gastric ulcers 
；Graham et al 1993]. To determine whether treatment with misoprostol could 
affect NSAID-induced GI complications, Silverstein et al 1995 conducted the 
Misoprostol Ulcer Complication Outcomes Safety Assessment ( M U C O S A ) 
study. Results showed a 4 0 % reduction in the overall rate of complications due 
to NSAID-related ulcers in a group of patients receiving 2QQug of misoprostol 
four times a day, as compared with patients receiving placebo. 
Although misoprostol is highly effective for preventing NSAID-induced 
ulcers, it has a number of side effects. These include diarrhea and because of the 
uterotonic effect of misoprostol, it is contraindicated in pregnancy and in 
women planning a pregnancy. 
1.3.3 Proton Pump Inhibitor 
Yeomans et al 1998 preformed a study to compare omeprazole and 
ranitidine for the prevention of recurrent GI ulcers in patients with arthritis to 
w h o m N S A I D therapy could not be discontinued. After 6 months treatment, 
20mg omeprazole daily was found to be superior to ranitidine with respect to 
healing and prevention gastroduodenal ulcers and erosions, as well as 
controlling dyspeptic symptoms. 
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A study conducted by Hawkey et al 1998 to compare 20mg omeprazole 
given once a day and misoprostol 200wg given twice daily for the prevention of 
recurrent ulcers in arthritis patients who were given N S A I D therapy. Results 
showed that the overall rates of successful treatment of ulcers, erosions, and 
symptoms associated with NSAIDs were similar for the two study groups and 
omeprazole was better tolerated than misoprostol. 
1.3.4 Selective COX-2 Inhibitors 
A logical way to prevent NSAID-induced gastropathy is to use drugs that 
are less likely to cause GI injury. Nearly three decades since Sir John Vane 
hypothesized that NSAIDs act by inhibiting the catalytic activity of the enzyme 
cyclooxygenase. It has been a decade since Needleman discover of two isoforms 
of C O X , COX-1 and COX-2 exist. The main concern using non-selective 
N S A I D medications is that, while relieving pain and inflammation, they also 
disrupt the homeostatic activities of the prostaglandins formed by C O X [Lipsky 
1999]. 
The discovery of COX-2 led to the hypothesis that COX-2 inhibitor could 
relieve pain and inflammation without disrupting the homeostatic functions 
medicated by COX-1 [Lipsky 1999]. 
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The first international workshop on COX-2 classified three types of 
COX-2 inhibitor, namely, non-specific C O X inhibitor, preferential COX-2 
inhibitor and. selective COX-2 inhibitor. Non-specific COX-2 inhibitor has no 
meaningful biologic or clinical difference in COX-1 or COX-2 inhibition. For 
preferential COX-2 inhibitor, this type of C O X inhibitor has some 
anti-inflammatory activity at low dose that inhibit COX-2 but not COX-1. 
Several studies have confirmed that the incidence of GI mucosal injury is 
reduced with the use of preferential COX-2 inhibitors. Distel et al 1996 
concluded that the safety of meloxicam appeared to be due to its preferential 
inhibition of COX-2, with a minimal effect of COX-1. In contrast, nabumetone 
appeared to inhibit COX-2 at low dose. At higher dose, the preferential 
inhibition of COX-2 is diminished [Roth et al 1993]. For selective COX-2 
inhibitor, this type of C O X inhibitor has > 100-fold preference for COX-2 
inhibition. Even at maximal therapeutic dose, there is no inhibition of COX-1 in 
vivo [Cheung 1999]. 
1.3.4.1 GI safety of selective COX-2 inhibitors 
The U S Food and Drug Administration (FDA) licensed two selective 
COX-2 inhibitors, celecoxib and rofecoxib in 1999. Both of them were reported 
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to be superior to placebo in relieving the symptoms of inflammation and pain in 
patients with O A and R A . The F D A approved celecoxib for the relief of signs 
and symptoms of O A and R A , management of acute of pain in adults, treatment 
of primary dysmenhorrea and reduction of the number of adenomatous 
colorectal polyps in familial adenomatous polyposis. O n the other hand, 
rofecoxib was approved for the relief of signs and symptoms of O A and R A , 
management of acute of pain in adults and treatment of primary dysmenhorrea. 
In an observational study conducted by Mamdani et al 2002 to compare the 
use of selective COX-2 inhibitors, rofecoxib and celecoxib with non-selective 
NSAID, diclofenac plus misoprostol in patients 66 years and over on the risk of 
upper GI hemorrhage. Results of this population based observational study 
revealed a lower short-term risk of upper GI hemorrhage for selective COX-2 
inhibitors compared with non-selective NSAID. 
Deeks et al 2002 conducted a systematic review of all published and 
unpublished trials to determine if celecoxib is as effective as other NSAIDs for 
the treatment of O A and R A and if there is evidence of greater GI tolerability 
and safety. The results showed that celecoxib is as effective as other NSAIDs 
for relief of signs and symptoms of O A and R A and has significantly improved 
GI safety and tolerability. 
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In a double-blind, double dummy, randomized, parallel trial to compare the 
efficacy, safety and tolerability of long term therapy with celecoxib and 
diclofenac in patients with R A . Celecoxib showed sustained anti-inflammatory 
and analgesic activity similar to diclofenac, with a lower frequency of upper GI 
ulceration or adverse events, and better tolerability [Geis et al 1999'. 
The GI safety of selective COX-2 inhibitors has been analyzed in two large, 
randomized double blind clinical trials, the Vioxx Gastrointestinal Outcomes 
Research (VIGOR) and Celecoxib Long term Arthritis Safety Study (CLASS). 
1.3.4.1.1 Gastrointestinal outcomes research of rofecoxib 
The V I G O R trial enrolled 8076 patients with R A and compared the 
occurrence of GI toxicity with rofecoxib 50mg per day or naproxen 500mg bid 
for a median of nine months (maximum 17 months). Aspirin was not permitted 
in the trial. 
The main objective of the V I G O R trial was to determine whether rofecoxib 
has an improved GI safety profile compared with a non-selective NSAID, 
naproxen. The incidence of confirmed clinical upper GI events, including 
perforation, obstruction, symptomatic ulcers and upper GI bleeding was chosen 
as primary end point. Complicated upper GI events, including perforation, 
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obstruction, and severe bleeding with > 2 gram decrease in hemoglobin, 
constituted the secondary end point of the V I G O R trial. Based on the final 
results of this study, in patients with R A , treatments with rofecoxib at two times 
the maximum recommended doses for relieving symptoms of O A is associated 
with significant lower rates of upper GI events, complicated upper GI events 
and GI bleeding, compared with treatment with a standard dose of naproxen 
Bombardier et al 2000:. 
1.3.4.1.2 Celecoxib Long term Arthritis Safety Study 
C L A S S trial was a randomized double-blind trial of 8059 patients with O A 
or R A randomly assigned to receive celecoxib 400mg twice daily (2 to 4 times 
the maximum dosage of R A and OA), ibuprofen 800mg 3 times per day or 
diclofenac 75mg twice daily. A major difference between V I G O R and C L A S S 
studies is that in CLASS, patients were permitted to take aspirin (> 325mg per 
day) for cardiovascular prophylaxis. Although the study last 13 months, only the 
first 6 months results were published, and the final results are only available on 
the F D A web site. 
The primary end point of the C L A S S trial was the incidence of 
prospectively defined ulcer complications, including bleeding, perforation, and 
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gastric outlet obstruction; the secondary GI safety outcome included ulcer 
complications and symptomatic ulcers. Although the incidence of ulcer 
complications with celecoxib was lower than with NSAIDs taken together or 
separately, the differences between the observed rates were not statistically 
significant for any comparison in an intent-to-treat analysis. The incidence of 
the secondary endpoint with celecoxib was significantly lower compared with 
ibuprofen, but not with diclofenac. 
In conclusion, celecoxib at 2 to 4 times the maximum recommended dose 
for R A and O A is associated with a lower but non-significant incidence of ulcer 
complications and with a significant lower rate of ulcer complications and 
symptomatic ulcers compared with therapeutic doses of ibuprofen [Silverstein et 
a/2000]. 
1.3.4.2 Cardiovascular toxicity of NSAIDs 
Hypertension and arthritis represent common comobid conditions leading 
to the frequent co-administration of NSAIDs and anti-hypertensive medications. 
1.3.4.2.1 Cardiovascular toxicity of non-selective NSAIDs 
Non-selective inhibition of C O X enzymes results in inhibition of 
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prostaglandin synthesis and is associated with antinatriuretic and 
vasoconstrictor effects. These effects have consequence on blood pressure 
control. Johnston et al 1994 reported an average increase in mean arterial 
pressure of 5.5 m m H g in patients using non-selective NSAIDs. 
1.3.4.2.2 Cardiovascular toxicity of selective COX-2 inhibitors 
Selective COX-2 inhibitors have become a widely use class of agents for 
the treatment of arthritis since 1999 because of their improved GI safety 
compared with non-selective NSAIDs. During the past years, the effect of these 
agents on cardiovascular events has become a concern that has led to 
controversy. 
Further questions about the cardiovascular safety of rofecoxib were raised 
in 2001 by an overview of the clinical data. In the case of rofecoxib, results of 
the V I G O R made cardiovascular safety a critical issue: the rate of myocardial 
infraction was four-fold; the rate of thrombotic events was two-fold higher in 
the rofecoxib group compared with naproxen. These data prompted the U S F D A 
to initiate a label change in 2002, highlighting the potential cardiovascular risks 
of rofecoxib. Currently, there are conflicting data as to whether selective COX-2 
inhibitors such as rofecoxib and celecoxib as a class can also result in blood 
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pressure elevations. 
To date, despite the results from V I G O R study reported cardiovascular 
thromboembolic (TE) risk arouse, the published data from other randomized 
controlled clinical trials, retrospective observational studies provide a 
conflicting body of evidence on the T E risk with selective C O X - 2 inhibitors. 
In C L A S S trial, no difference in T E events between celecoxib and 
conventional NSAIDs used in the C L A S S trial has been reported and the risk of 
cardiovascular events associated with celecoxib even supra-therapeutic dose is 
similar to that of the non-selective NSAIDs. 
Solomon et al 2004 preformed a retrospective case reported study and 
reported an increased relative risk of new onset hypertension with rofecoxib but 
not with celecoxib in patients aged 65 years or older. Besides, in a randomized, 
parallel group, double blind study involved more than 1000 osteoarthritis 
patients also found that significantly more patients in the rofecoxib group 
compared with the celecoxib group developed increased systolic blood pressure 
[Whelton et al 2002]. 
O n September 30，2004, Merck announced a voluntary withdrawal of 
rofecoxib worldwide. The risk of cardiovascular events became more apparent 
when the company carried out a colon cancer chemoprevention trial called 
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Adenomatous Polyp Prevention O n Vioxx (APPROVe). This 3-year clinical trial 
was a multicenter, placebo controlled trial of 2600 patients designed to evaluate 
the efficacy of rofecoxib in preventing the recurrence of colorectal polyps in 
patients with a history of colorectal adenoma. A n interim analysis reported that 
an almost two fold increase relative risk for serious cardiovascular events, 
including heart attacks and strokes after 18 months treatments compared with 
placebo. 
O n December 17, 2004, Pfizer informed the U S F D A that the Adenoma 
Prevention with Celecoxib (APC) trial had been halted. The A P C trial was a 
thirty-three months trial of a 400mg to 800mg daily dose of celecoxib for 
prevention of colonic polyps. Results showed that patients taking these supra 
therapeutic doses were 2.5 times more likely to have cardiovascular events 
[Pfizer web site:. 
Coxibs of the second generation such as valdecoxib，etoricoxib, 
lumaricoxib and paracoxib process a higher COX-2 selectivity than the first 
COX-2 generation as well as proven efficacy in the treatment of pain and 
arthritis. However, on April 7, 2005, the U S F D A has requested Pfizer 
voluntarily withdrawn valdecoxib in the United State. Valdecoxib has been 
demonstrated to be associated with an increased risk of serious adverse 
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cardiovascular events in two short-term trials in patients immediately 
post-operative from coronary artery bypass graft surgery [FDA web site]. O n the 
other hand, Schnitzer et al 2004 has conducted the Therapeutic Arthritis 
Research and Gastrointestinal Event Trial (TARGET) published in The Lancet, 
failed to demonstrate a statistically significant difference in cardiovascular side 
effects between lumiracoxib and naproxen or ibuprofen, with more people 
taking lumiracoxib had a myocardial infraction. Definitive evidence of 
cardiovascular risk and benefits of these agents will require prospective 
randomized clinical trials. 
Since rofecoxib and valdecoxib were found to be associated with 
cardiovascular complications and have been withdrawn from the market, it 
appears that this is a class effect. But still most studies seem to show that 
celecoxib does not pose nearly a high risk of cardiovascular events as rofecoxib. 
Celecoxib is the only selective COX-2 available in the states; even the F D A 
places strong black label warnings on the drug. It is clear that not all selective 
COX-2 inhibitors are created equal. At structural level, valdecoxib, celecoxib 
and rofecoxib share a three-ring structure, but all differ in the central ring, and 
very small changes on these rings can made a great difference (Figure 2). 
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Figure 2 Selective COX-2 Inhibitors: Chemical Structures 
Celecoxib Valdecoxib 
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Rofecoxib and valdecoxib in development are highly selective for COX-2. 
Celecoxib, however, inhibits COX-2 to a lesser extent and can also partially 
inhibit COX-1. Besides, celecoxib has a shorter half-life than rofecoxib. It is 
unclear why rofecoxib may be more likely to increase blood pressure than 
celecoxib at commonly used clinical dose. Possible explanations on 
cardiovascular events by similar agents may be related to inherent 
pharmacological difference between the two drugs or differences in the extent of 
COX-2 inhibition at dose considered to be clinically equivalent [Howes and 
Krum 2002]. 
1.4 Guidelines on the management of osteoarthritis and rheumatoid arthritis 
Recently, selective COX-2 inhibitors, with claims to have better GI safety 
profiles, were available in market. As there is a wide range of therapeutic agents 
available for the management of O A and R A , several parties have developed 
guidelines to address the role of selective COX-2 inhibitors relative to 
non-selective NSAIDs. 
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1.4.1 American College of Rheumatology subcommittee 
These guidelines outlined the use of nonpharmacologictherapies for 
patients with O A (Table 1) as well as the use of pharmacologic agents (Table 2). 
For patients who are at increased risk for a serious upper GI event, selective 
COX-2 inhibitor or the use of non-selective NSAIDs with gastroprotective 
agents are treatment options [Altman et al 2000:. 
Table 1 Nonpharmacologic therapy for patients with osteoarthritis 
Patient education 
Weight loss 




Table 2 Pharmacologic therapy for patients with osteoarthritis 
Acetaminophen 
Selective COX-2 inhibitor 
Non-selective N S A I D plus misoprostol or a proton pump inhibitor 
Nonacetylated salicylate 
Other pure analgesics 
Tramadol/Opioids 
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1.4.2 National Institute for Clinical Excellence (NICE) 
This guideline recommends that selective COX-2 inhibitor should be used 
instead of non-selective NSAIDs in patients who are at high risk of developing 
serious GI problems [NICE 2001]. 
1.4.3 Hong Kong Hospital Authority (HA) 
In July 2001, Hospital Authority formed a working group of developing 
guidelines to the use of selective COX-2 inhibitor. Patients are stratified into 
three groups based on the risk factors for serious GI hemorrhage with N S A I D 
therapy (Table 3). The guideline recommended that a cytoprotective agent such 
as proton pump inhibitor (PPI) or high dose misoprostol (600mg/day) should be 
given to patients at high risk (Group A). Selective COX-2 inhibitor is 
recommended for moderate risk (Group B) patients. 
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Table 3 Risk factors for serious GI bleeding with N S A I D therapy 
Groups Risk factors 
A Proven history of peptic ulceration by endoscopy; 
(High risk) or concomitant use of anticoagulants or moderate 
high dosages of corticosteriods ； Group B patients 
taking aspirin 
B Age > 75; or 
(Moderate risk) Multiple co-morbid illnesses rendering the patient more 
vulnerable to the hazards of gastrointestinal hemorrhage 
C Individuals not belonging to groups A or B 
(Low risk)  
1.5 Cost of illness of upper GI events in the setting of an emergency room of a 
regional hospital in Hong Kong and cost analysis of selective COX-2 
inhibitor with non-selective N S A I D plus gastroprotective agent 
Many health care organizations have employed disease management 
strategies on chronic diseases that have a significant long-term clinical and 
economic impact to improve quality and decrease costs. Pharmacoeconomics 
employs a number of tools to assist health care professionals in making 
decisions by identification, measurement, and comparison of the cost and 
consequence of medical interventions (e.g. drug, diagnostic tests) and their 
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impact on patients, health care systems and society. A number of different 
economic evaluations are available, such as cost of illness, cost effectiveness, 
cost benefit, cost utility, and cost minimization analysis. 
Hospital Authority is a public health organization in Hong Kong. The 
operation of H A is based on funding by Government. In 2003/4, H A incur an 
operating deficit despite saving programs put in place across the organization. 
With Government budget cut, healthcare and pharmaceutical professionals in 
hospitals are demanded to use their limited resources in a way to improve the 
quality of health care services with minimal cost. 
1.6 Objectives 
The present thesis aims to estimate: 1) the cost of illness of upper GI 
events in the setting of an emergency room of a regional hospital in Hong Kong 
and 2) to conduct cost analysis of celecoxib versus diclofenac with omeprazole 
using incidence of GI events from (a) local randomized clinical trial and (b) 
large randomized clinical trial. 
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Chapter 2 Cost of illness of upper GI events in the setting of an 
emergency room of a regional hospital in Hong Kong 
Arthritis is a high prevalent disease and cause morbidity and disability 
particularly in the elderly. In a survey coordinated by the census and statistics 
department in Hong Kong in 2000, 40.6% of seniors aged 60 or above reported 
having arthritis. 
Like many other places in the world, Hong Kong's population is ageing, 
the number of seniors increased from about 344,000 in mid-1981 to over 
753,600 in mid-2001. The proportion of the population aged 65 or above will 
continue to grow from 11% in 2001 to 24% in 2031, accounting for one of the 
four Hong Kong people. 
The Hospital Authority is an independent organization established on Dec 
1,1990 to manage all public hospitals in Hong Kong. It is the major provider of 
medical services, providing hospital care and currently manages 43 public 
hospitals and institutions. As at Dec 31, 2001, H A managed a total of 29,022 
hospital beds. In 2001/2002，there was a total of 1,213,600 in-patient and day 
patient discharge and death. 
In 2001-2002, the Hospital Authority spent 17.5 million on health care 
services for every 1000 elderly persons aged 65 or above. Ageing population 
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has a large impact on Hong Kong healthcare system. 
Nonsteroidal anti-inflammatory drugs are widely used to treat chronic 
arthritis pain. GI side effects are frequent in patients taking NSAIDs medication. 
N S A I D users are almost 4 times greater risk than non-users of developing a 
clinical upper gastrointestinal event [Hernandez et al 2000 • 
During 1999-2001, in-patient discharge for peptic ulcers to H A and private 
hospitals in Hong Kong increased by 3 % from 10,514 to 10,915. During the 
same period, mortality rate due to peptic ulcers declined by 89% from 98 to 11. 
For admission of peptic ulcers in H A hospitals, the annual figures increased by 
2 % from 9,127 to 9,296. From the available figures, the in-patient discharge 
from private hospitals increased by 10 folds, from 1404 to 14,634 [Hospital 
Authority web site:. 
In a local study, Chan et al 1996 investigated the relationship between 
upper GI hemorrhage and drug use among Chinese patients admitted to a 
regional hospital in Hong Kong concluded that upper GI hemorrhage from 
primarily peptic ulcer is mainly associated with the use of NSAIDs and NSAIDs 
appear to alter the profile of GI symptoms. While clinicians are well aware of 
many of the adverse effects associated with non-selective NSAIDs, very few 
studies have been conducted on the cost of upper GI events associated with the 
27 
use of non-steroidal anti-inflammatory drugs in Hong Kong. 
The objective of the study is to evaluate the cost of illness of upper GI 
events in the setting of an emergency room of a regional hospital in Hong Kong. 
In view of high risk of GI complications associated with the use of NSAIDs, 
this study intends to estimate the economic burden of severe GI adverse events 
in Hong Kong in order to serve as a benchmark for the economic evaluation of 
new therapy such as selective COX-2 inhibitors. 
2.1 Methods 
2.1.1 Study site 
The United Christian Hospital (UCH) is a teaching hospital for medical 
students of the Chinese University of Hong Kong with 1000 beds in 1999，is 
one of the two acute general hospitals serving the population of East Kowloon 
region. 
2.1.2 Cohort participants 
The cohort consists of all patients admitted to Accident and Emergency 
(A&E) Department of the United Christian Hospital with complaints of upper 
GI events, which include gastritis, duodenitis, gastric and duodenal ulcer, 
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perforation or GI bleeding and received treatment for the GI events on January 1, 
1999 to March 31,1999. Patients with mild GI events such as dyspepsia were 
not including in the study. Patients with upper GI events were identified based 
on their discharge diagnosis. Study outcomes were the utilization and costs of 
medical care provided during follow-up and the treatment of GI disorders. 
Patients with GI events including gastritis, duodenitis, gastric ulcer ( U C H code 
531), duodenal ulcer (code 532), GI hemorrhage (code 578.9) and GI 
perforation (code 533.1-2 and 533.5-6) were recruited but excluded esophageal 
varices or strictures, GI malignancies, coagulopathies and recent history of 
alcoholism. Those conditions showed little evidence of association with N S A I D 
exposure. 
2.1.3 Resource data collection 
Resource utilization questionnaire was developed to collect information 
about medical resources based to manage different GI events. Data collected 
were limited to the information about the medical resources specifically 
associated with the GI events. Resources considered included medications for 
treatment of GI events; diagnostic tests, oesophagogastroduodenoscopy (OGD), 
clinic visits, accident and emergency room visits, GI procedures and 
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hospitalizations resulted from a GI event. N o indirect medical cost data were 
collected. Total resources utilized three months (to encompass the event, 
treatment and follow-up) were outlined. 
2.1.4 Cost data 
The healthcare resources used by each patient were retrieved from medical 
records and only direct medical health care costs were considered. The cost was 
calculated in Hong Kong dollars. The cost of major health care resources items 
was summarized in Table 4. 
Table 4 Cost of major health care resources items 
Cost items H K $ * 
Medications 
Clarithromycin SOOmg tablet 15 
Amoxicillin 1 g tablet 0.72 
Famotidine 20mg tablet 0.26 
Cimedidine 400mg tablet 0.34 
Cimedidine 200mg injection 3.3 
Omeprazole 20mg tablet 10.21 
Omeprazole 40mg injection 79.8 
O G D / per visit 3500 
Clinic visit / per visit 455 
Accidient and emergency room visit / per visit 532 
Hospitalization / per day 3010 
* 1 USD=7.8 H K D 
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2.1.5 Statistical Methods 
Data analysis 
Descriptive statistical analysis was performed using SPSS for Windows 
version 10.1 (SPSS, Chicago, IL, USA). P values less than 0.05 were considered 
significant. 
2.1.6 Study perspective 
The study was conducted from the perspective of a public health 
organization. Drug cost was based on Hospital Authority acquisition cost. The 
cost for health care resources was obtained from the Hong Kong Gazette. 
2.2 Results 
2.2.1 Demographic data 
A total of 367 patients admitted to A & E Department and fulfilled the 
inclusion criteria and 17 patients had multiple admissions for more than one 
episode of GI events within the 3 months inclusion period. Therefore, 385 cases 
were included in the analysis. The baseline characteristics of the patients were 
summarized in Table 5. The mean age of the study population (SD) was 62 
years (20.6) and 62 % were male. The distribution of various GI events was 
31 
shown in Table 6. GI hemorrhage (41%) was the most common diagnosis of GI 
events. 
Table 5 Demographics characteristics of the patients 
Characteristics  
N o of patients 367 
Mean age (S.D) 62 (20.6) 
Distribution by age - no. of patients (%) 
<65 159 (43) 
> 65 208 (57) 
Gender (%) 
Male 226 (62) 
GI events - no. of patients (%) 
Gastritis 45 (12) 
Duodenitis 3 (1) 
Gastric ulcer 58(16) 
Duodenal ulcer 85 (23) 
GI hemorrhage 155 (42) 
GI perforation 21 (6) 
More than 1 episode of GI event between the 
study periods - no. of patients (%) 17 (4) 
Coexisting medical conditions - no. of patients 
(%) * 106 (29) 
Previous use of NSAID/aspirin - no. of patients 
^ 38(10) 
* Medical conditions include ischemic heart disease, 
hypertension and angina. 
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Table 6 Distribution of upper GI complaints in U C H from Jan 1 to Mar 31, 
1999 
Number of upper GI complaints in U C H from Jan 1 to 
Mar 31,1999 N=385   
GI events N o of patients ( % ) 
GI HEMORRHAGE 158 ( 4 1 ) 
DUODENAL ULCER 89 (23 ) 
GASTRIC ULCER 67 ( 17 ) 
GASTRITIS 45 ( 1 2 ) 
GI PERFORATION 23 ( 6 ) 
DUODENITIS 3 ( 1 ) 
TOTAL 385 
2.2.2 Total direct medical cost of upper GI complaints in U C H 
The total direct medical cost for the treatment of upper GI events between 
ist Jan to 3ist Mar 1999 was $12,412,796 (1 U S D 二 7.8 H K D ) . Of the total 
direct medical cost regarding upper GI events, 11% of the total direct medical 
cost was for gastritis, 1 % of the total direct medical cost was for duodenitis, 
15% was for gastric ulcer, 17% was for duodenal ulcer, 4 7 % was for GI 
bleeding and 9 % was for GI perforation (Table 7). Fifty nine percent of the total 
direct medical cost of upper GI events was for hospitalization, 1 % was for clinic 
visits, 1 % was for prescribed medications, 25% was for O G D , 6 % was for 
diagnostic tests, 1% was for emergency room visits and 7 % was for GI 
procedures (Table 8). For patients who had a history of non-selective N S A I D 
I 
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use had a total medical cost that were on average of $3024 (9%) higher than for 
patients who did not use N S A I D (Table 9). 
Table 7 Partitioning of total direct medical costs ( H K D ) of upper GI 
complaints in U C H 1'' Quarter 1999 
Total cost of upper GI complaints in U C H between Jan 1 to Mar 31,1999 
Events Total Cost (%) Mean cost (SD) 
GI HEMORRHAGE 5,881,752 ( 4 7 ) 37,226 (34,690) 
DUODENAL ULCER 2,058,924 ( 17 ) 23,133 (13,423) 
GASTRIC ULCER 1,910,533 ( 15 ) 28,515 (18,785) 
GASTRITIS 1,371,116 ( 11 ) 30,469(15,449) 
GI PERFORATION 1,126,432 ( 9 ) 48,975 (28,458) 
DUODENITIS 64,038 ( 1 ) 21,346(1,792) 
TOTAL |l2，412,796 |32，241 (27,012) 
Table 8 Breakdown of health care resources used for treating of upper GI 
complaints in Quarter 1999 in U C H 
Resources used to treat upper GI complaints — 
RESOURCES Total Cost (HKD) ( % ) 
HOSPITALIZATION 7,286,640 ( 59 ) 
OGD 3,105,605 ( 25 ) 
GI PROCEDURE 858,795 ( 7 ) 
DIAGNOSTIC TEST 760,186 ( 6 ) 
MEDICATION 117,909 ( 1 ) 
CLINIC VISIT 90,545 ( 1 ) 
AE VISIT 193 ,116 (1 ) 
TOTAL 12,412,796 
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Table 9 Average total direct medical costs of patients reported use of 
NSAID/aspirin in Quarter 1999 in U C H 
Mean cost to treat upper GI complaints for patients reported use of 
NSAID/aspirin  
NSAID/aspirin Mean cost (SD)*  
No reported use (n=38) 31,919 (26,474) 
Reported use (n=329) 34,943 (31,410) 
* p-0.499 
2.3 Discussion 
GI side effects related to N S A I D are responsible for a large economic 
burden in the health care system. In the US, the annual medical costs associated 
with GI complications were estimated to be US$ 3.9 billion [Chevat et al 2001；. 
2.3.1 Total direct medical cost of upper GI events 
The present study represented one of the first economic analyses on upper 
GI adverse events in Chinese population. A total of 385 cases of upper GI 
adverse events were being managed in U C H during the quarter of 1999. 
Analysis was conducted from the perspective of a public health organization in 
Hong Kong. The projected total medical cost for the treatment of upper GI 
events in U C H in year 1999 would be $49,651,184. The largest portion of the 
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direct cost was due to hospitalization, followed by the cost of O G D . The 
resources consumed and the total cost associated with an event is generally 
consistent with the severity of the event. Ulcer is less resource consuming and 
cost less to manage than GI hemorrhage. The GI events that required 
hospitalization were the most costly events because of the burden of hospital 
stays. O G D were observed to perform routinely for differential diagnosis of the 
adverse GI events. The total cost of prescribed medication for the treatment of 
GI adverse events constituted only 1 % of the total costs. 
Prior studies suggested that medications and hospitalization are the major 
determinants of treating GI toxicity associated with N S A I D used [Smalley et al 
1996]. Some reported that hospitalization alone account for the largest portion 
ofGI-related cost in N S A I D users [Mcintosh 1996] [Chevat et al 2001], 
whereas others have reported that medications alone accounted for most of the 
cost in treating GI adverse events [Laine et al 2003]. 
In this present study, hospitalization alone accounted for almost 60% of the 
direct cost in treating upper GI complaints. The economic burden of R A was 
estimated in England that the largest portion of the direct cost (28%) was due to 
hospitalizations [Mcintosh 1996]. Chevat et al 2001 conducted an economic 
analysis of health care resource utilization and costs of treating gastrointestinal 
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toxicity associated with N S A I D in 11 countries in patients with O A and R A . 
The total per event cost varies from $US 229 to $US 795 for GI ulcer and from 
U S $ 1,787 to $US 6,729 for serious GI events requiring hospitalization. 
Resources data collection for the estimation of Gl-related events costs were 
based on the results of resource utilization questionnaires which showed that 
costs were primarily driven by the rate of endoscopy for ulcer. For serious GI 
events, hospitalizations were the key cost driver. Our findings show that 
hospitalizations were the key cost drivers for all GI events studied. This may be 
explained by the high incidence of GI bleeding in our study cohort. Smalley et 
al 1996 conducted a retrospective study of 75,350 elderly patients at least 65 
years of age. Medical care cost such as hospitalizations/emergency room visits 
for peptic ulcers, gastritis/duodenitis, and GI bleeding, outpatient upper and 
lower GI tract radiologic and endoscopic examinations, and gastroprotective 
medications used for the diagnosis and treatment of GI disorders attributed to 
the use of NSAIDs other than aspirin were calculated. Results show that for 
both N S A I D users and non-users, medications accounted for the largest 
component of costs, 49% and 48% respectively. Hospitalizations accounted for 
38% for N S A I D users and 37% for non-users. Laine et al 2003 conducted a 
longitudinal, retrospective cohort study to access upper and lower GI related 
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resources use in patients with chronic use of selective COX-2 inhibitors and 
non-selective NSAIDs suggested that the cost of medications represented the 
largest portion of Gl-related costs in N S A I D users. However, the cost of 
medications represented only a minor portion of the Gl-related cost in this study 
may be due to acquisition cost of the medications is lower than in other 
countries. 
2.3.2 Cost of upper GI events associated with N S A I D usage 
Our analysis demonstrated a slight increase in the resources used to treat 
upper GI events for patients who had a history of non-selective N S A I D use 
comparing to patients with no reported N S A I D use, although the difference did 
not reach statistical significance. This may be explained by small number of 
subjects had reported a history of non-selective N S A I D therapy usage. As w e 
did not have information on N S A I D usage from our study cohort, the 
assumption was not verifiable due to limitations of the database. 
2.3.3 Low dose aspirin on NSAID-induced GI toxicity 
Practice guidelines from the American College of Cardiology and 
American Heart Association recommend chronic low-dose aspirin for secondary 
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cardiovascular prevention [Ryan et al 1999]. Although aspirin is increasing used 
for its anti-platelet effects as prophylaxis in cardiovascular disease. It is proven 
that, even at low doses, aspirin can cause GI bleeding. It is documented that, the 
use of multiple NSAIDs especially in the elderly population for the treatment of 
arthritis simultaneously increase the risk of GI bleeding. In this study 10% of 
patients previously used N S A I D or aspirin. It is possible that the cost for 
treatment of the upper GI events may have been overestimated because aspirin 
could have increased the occurrence of GI adverse events. At present, economic 
analysis has not been taking into account the cost of arthritis and cardiovascular 
disease in Hong Kong. 
2.3.4 Limitation 
The present study had several limitations. The study database did not 
contain information on over the counter use of NSAIDs or aspirin. There was 
likely misclassification of non-selective N S A I D use due to subject's use over 
the counter preparations of which we had no knowledge. Self-medication is a 
common practice in Hong Kong in patients with co morbidities [Chan et al 1992 
and is common occurrence of peptic ulcer symptoms. Further misclassification 
could be induced by obtaining NSAIDs from over the counter, causing 
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underestimation the true cost of GI disease attributed to NSAIDs. Clinical 
studies have indicated that non-selective NSAIDs are particularly prone to cause 
GI problems than selective COX-2 inhibitors. The value of selective COX-2 
inhibitors depends on what kind of resources and costs that can be spared if GI 
events are prevented. W e therefore purposely choose to investigate the cost of 
upper GI events in year 1999 before selective COX-2 inhibitor became available 
for trial on patients in H A hospitals to eliminate the effect of COX-2 on the cost 
of the upper GI events associated with NSAIDs. 
Besides, it is difficult to access the exact size of the share of the cost of 
ulcer disease that originates from the use of NSAIDs. A n increase in the use of 
NSAIDs may have increase the share, while the co-prescription of anti-ulcer 
medications to prevent ulcer may have reduced or increased the total cost. 
A n inherent limitation of retrospective database study is that the 
populations are not randomized to treatment, so selection bias resulting from 
prescriber treatment decisions may occur. The data was drawn from one of the 
major H A hospital which may also limit the generalizability of the results. 
Besides, the cost estimation was based on patients with NSAED-related 
upper GI events who presented to the casualty department and patients with 
mild symptoms such as dyspepsia were excluded. Finally, only direct medical 
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cost was examined and did not investigate the decrease in quality of life or other 
consequence of the adverse events. 
2.3.5 Future study 
Future study should be conducted to broaden the perspective of the study 
to society level by introducing the indirect costs such as loss of production or 
wages and the intangible costs, namely, costs related to the reduced quality of 
life that accompany chronic disease in economic analysis. 
2.4 Conclusion 
In conclusion, a considerable amount of money is spent in U C H for the 
year 1999 for the treatment of upper GI events. This study reveals that GI 
hemorrhage was the most common diagnosis of GI events with hospitalization 
accounted for the largest portion of the direct cost. While the excess cost of 
treating severe GI events are expected, the data presented make it possible to 
understand the consequence of targeting new and safer but more expensive 
therapeutic options to patients most likely to benefit from them clinically. While 
it is true that the reduced risk and improved tolerability of these newer agents 
confer benefits that are not completely represented in terms of the potential 
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reduction in health care utilization, it is critical to determine the baseline cost for 
non-selective N S A I D associated GI adverse effects so that the cost effectiveness 
of different treatment strategies can be determined. Our finding add important 
data to literature that may allow clinicians and policy makers to quantify the 
economic consequence of using selective COX-2 inhibitors may be potential 
means of reducing health care resources used to treat upper GI complaints 
associated with non-selective NSAIDs. 
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Chapter 3 Cost analysis of selective COX-2 inhibitor versus non-selective 
NSAID with gastroprotective agent 
With increasing number of therapeutic options for non-selective NSAIDs, 
precise estimate of the benefits and costs of pharmacotherapy become more 
important. Determination of drug efficacy does not automatically imply 
economic benefit. Establishment of economic benefit requires a vigorous 
analysis of both the benefits and the total costs of a given therapy. 
In the United sates, an estimated 10,700 patients are hospitalized and 
16,500 die each year as a result of NSAID-related ulcer complication [Singh et 
al 1999]. Patients with a history of ulcer bleeding who use N S A I D are at a high 
risk of GI complication. According to the H A Corporate Drug Dispensing 
History (CDDH) data, -75,500 patients were prescribed NSAIDs in 99/00 in 
Hong Kong. The simple choice of the cheapest preparation seems a logical way 
of choosing a preparation. In practice, both effectiveness and side effects 
produce quite complex issues of choice since the introduction of selective 
COX-2 inhibitors. Current clinical studies indicated that concurrent therapy 
with NSAIDs and misoprostol or proton pump inhibitor reduced the risks of 
ulcers [Jeffrey et al 1995, Grahm et al 2002]. In guidelines developed by the 
American college of rheumatology subcommittee on osteoarthritis, it 
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recommended the use of selective COX-2 inhibitors or non-selective NSAIDs 
plus misoprostol or proton pump inhibitor. Spiegel et al 2003 studied the cost 
effectiveness of selective COX-2 inhibitor in management of chronic arthritis 
using decision model and suggested that selective COX-2 may provide an 
acceptable incremental cost-effectiveness ratio in patients with bleeding ulcers 
but not for patients with average risk. Zabinski et al 2001 compared the cost and 
clinical consequence of selective COX-2 inhibitor with non-selective NSAIDs 
with gastroprotective agents, the model indicated that the use of selective 
COX-2 inhibitor could lead to the avoidance of a significant number of 
NSAID-induced GI events and the incremental cost of using selective COX-2 
inhibitor for patients > 65 years of age would not impose an excessive 
incremental impact on the healthcare budget. Laine et al 2003 have studied the 
gastrointestinal healthcare resources utilization with selective COX-2 inhibitors 
versus non-selective NSAIDs and concluded that patients switching from 
non-selective NSAIDs to selective COX-2 had a slight decrease in the 
proportion using Gl-related resources but not in GI cost. In Hong Kong, a cost 
analysis to compare the direct medical cost of selective COX-2 inhibitor versus 
non-selective NSAIDs with or without gastroprotective agents by decision 
model indicated that the use of selective COX-2 inhibitor was appeared to be 
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the least costly alternative for intermediate to high GI risk patients [You et al 
2002]. Nevertheless, most of the results as to whether selective COX-2 
inhibitors were more cost effective for the treatment of arthritis have only been 
addressed using decision tree models. In fact, results from these studies were 
controversial. 
Health care reform and escalating health care costs make the evaluation of 
resources utilization increasing important. Although clinical end-point is 
important in clinical practice, costs associated with the use of non-selective 
NSAIDs and selective COX-2 is also relevant to physicians and decision 
makers. 
Apart from these predictions based on overseas studies and on analytical 
decision models, very few data has been reported on the cost effectiveness 
comparing selective COX-2 inhibitor and non-selective NSAIDs based on 
prospective local clinical study. 
The objective of this study was to evaluate the economic impact of 
celecoxib versus diclofenac with omeprazole using incidence of GI events from 
(a) local randomized clinical trial and (b) large randomized clinical trial. The 
pharmacoeconomic data obtained will be a useful tool for clinicians and health 




3.1.1 Local randomized clinical trial 
3.1.1.1 Study population 
The results of a local randomized controlled clinical trial conducted in a 
teaching hospital were analyzed [Chan et al 2002]. 287 patients with 
rheumatoid arthritis, osteoarthritis, and other forms of arthritis who presented 
with ulcer bleeding as confirmed by endoscopy were included in the analysis. 
After ulcer healing as confirmed by follow-up endoscopy, patients with a 
negative test for Helicobacter pylori or successful eradication of H.pylori were 
randomized to received celecoxib 200mg twice daily or extended-release 
diclofenac 75mg twice daily plus 20mg omeprazole daily for six months. 
Patients with a history of gastric or duodenal surgery other than a patch repair; 
and concomitant use of anticoagulant agents or corticosteroids; and the presence 
of erosive esophagitis, gastric-outlet obstruction, renal failure, terminal illness 
or cancer were excluded in the study. 
In the intent to treat analysis, 144 patients were randomly assigned to 
receive celecoxib and 143 patients were assigned to receive diclofenac plus 
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omeprazole. The probability of recurrent bleeding during the six-month period 
was 4.9 % for patients who received celecoxib and 6.4 % for patients who 
received diclofenac plus omeprazole. 
3.1.1.2 Cost data 
Analysis was conducted from the perspective of a public health 
organization, considering only direct medical health care costs. The cost of 
routine management and management of recurrent ulcer bleeding for each 
patients were estimated. Cost of routine management included the resources 
utilized by the patient for routine follow-ups and differential diagnosis of 
suspected bleeding. The resources utilized to manage ulcer bleeding were 
recorded and calculated for cost of recurrent bleeding. The healthcare resources 
used by each patient include routine follow-up during the 6-month study period 
and the management of recurrent ulcer bleeding were retrieved from medical 
records. Costs of medications (including study medications and medications 
used for the management of recurrent ulcer bleeding) were based on hospital 
authority specific acquisition cost. The cost for other target types of health care 
resources included diagnostic tests; O G D ; clinic visits; accident and emergency 
room visits and hospitalization are obtained from the Hong Kong Gazettes. The 
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cost of major health care resources items was summarized in Table 10. 
Table 10 Cost of major health care resources items 
Cost items H K $ * 
Medications 
Celecoxib 200mg twice daily 8 
Diclofenac 75mg twice daily 4.9 
Omeprazole 20mg daily 10.21 
O G D / per visit 3500 
Clinic visit / per visit 455 
Accident and emergency room / per visit 532 
Hospitalization / per day 3010 
* 1 USD=7.8 H K D 
3.1.1.3 Statistical Methods 
The direct medical costs were expressed as median (range) since the 
distribution was skewed. The statistical significances of difference between the 
direct medical costs of the two study groups were calculated using 
Mann-Whitney test. P values less than 0.05 were considered significant. 
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3.1.1.4 Sensitivity analysis 
One-way sensitivity analysis was performed to examine the effect of 
generic pricing of omeprazole on the direct medical cost of diclofenac plus 
omeprazole study group. 
The data and sensitivity analysis were calculated using Microsoft excel 
2000 (Microsoft Crop, U S A ) and SPSS for Windows version 10.1 (SPSS, 
Chicago, IL, USA). 
3.1.2 Large randomized clinical trial 
3.1.2.1 Study population 
Local cost of COX-2 inhibitor and non-selective N S A I D were applied to 
the results of the V I G O R trial. A total of 8,076 patients with rheumatoid arthritis, 
56% of who were receiving long-term glucocorticoid therapy was included in 
the analysis of the V I G O R trial. About 8 % of the patients had a history of GI 
perforation, hemorrhage, or symptomatic peptic ulcer. Patients were randomized 
to receive either 50mg/day rofecoxib, twice the recommended dose for relief of 
osteoarthritis symptoms, or 500mg naproxen twice daily for a median of nine 
months. Use of aspirin was not allowed in the V I G O R trial. 
The incidence of confirmed clinical upper GI events, which include 
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perforation, obstruction, symptomatic ulcers, and upper GI bleeding, was 
chosen as the primary end point of the study. Complicated upper GI events, 
including perforation, obstruction, and severe bleeding with > 2 gram decrease 
in hemoglobin, constituted the secondary endpoint of the V I G O R trial. The 
cumulative incidence of complicated upper GI events was 0.59 events per 100 
patients-years with rofecoxib and 1.37 events per 100 patients-years with 
naproxen, which represents a 57% relative risk reduction in favor for rofecoxib. 
One hundred and twenty-five patients would need to be treated with rofecoxib 
to avoid 1 complicated upper GI event in 1 year. 
3.1.2.2 Cost data 
Analysis was conducted from using incidence of GI events rates from the 
V I G O R (rofecoxib) trial. V I G O R study was chosen instead of C L A S S 
(celecoxib) since the rate of confirmed upper events reach statistical 
significance between the two treatment groups in V I G O R trial. Cost per GI 
events was calculated using data from U C H in Chapter two. 
3.2 Results 
In this section, results are presented separately for the two different 
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methods of calculation. All cost are in 1999 H K D . 
3.2.1 Local randomized clinical trial 
3.2.1.1 Demographic data 
A total of 286 patients were included in the analysis. One patient in the 
celecoxib group who experienced ulcer bleeding was excluded because of an 
incomplete medical record. The baseline characteristics of the patients were 
summarized in Table 11. The mean ages of the celecoxib group and the 
diclofenac plus omeprazole group were 66.5±14.2 years and 68.8±13.3 years 
respectively (p=0.154). 61 patients in the celecoxib group and 65 patients in the 
diclofenac plus omeprazole group were male. 
Table 11 The baseline characteristic of the patients 
Celecoxib Diclofenac 
(n 二 143) plus 
omeprazole(n 二 143) 
Male sex — no. of patients (%) 61(42) 65(45) 
Mean age — yr (SD) 66.5(14.2) 68.8(13.3) 
Recurrent ulcer bleeding 
-no. of patients (%) 6(4.2) 9(6.3) 
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3.2.1.2 Cost analysis 
The median total direct medical cost (cost for routine management and 
recurrent bleeding management) of the celecoxib group was significantly lower 
than diclofenac plus omeprazole group by 11% from $ 10,915 (range 
$10，915-$57,899) to $9,714 (range $9,714-$ 89,770) (p<0.0001) (Table 12). 
The median direct medical cost for the routine management in the celecoxib 
group was also significant lower than diclofenac plus omeprazole group by 11% 
from $ 10,915 (range $10,915-$28,048) to $9,714 (range $6,946-$26,179) 
(pcO.OOOl). Compared to the diclofenac plus omeprazole group, the median 
direct cost for recurrent bleeding in the celecoxib was significant higher by 64% 
from $8,466 (range $572-$29,851) to $23,210 (range $12,318-$65,823) 
(p 二0.036). 
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Table 12 Median total direct medical cost per patient of the celecoxib group 
and the diclofenac plus omeprazole group 
Median total direct medical cost (range) (HKD) 
Celecoxib (n=143) Diclofenac 
plus omeprazole(n=143) 
Medications 1,344(1,344-4,640) 2,545 (1,193-6,194) 
Clinic visits 1,820 (1,365-2,730) 1,820 (910-2,730) 
Diagnostic/Lab tests 3,050 (3,050-7,609) 3,050 (2,080-7,354) 
O G D * 3,500 (3,500-27,000) 3,500 (3,500-17,500) 
Emergency room visits 0 (0-1,596) 0 (0-532) 
Hospitalization 0(0-50,080) 0 (0-31,300) 
Total 9,714 (9,714-89,770) 10,915 (10,915-57,899) 
# Total direct medical cost includes cost for routine management and cost for 
management of recurrent bleeding 
* O G D = oesophagogastroduodenoscopy 
3.2.1.3 Sensitivity analysis 
This study adopted oral omeprazole price of year 1999. Recently, generic 
oral omeprazole became available in Hong Kong. The effect of generic pricing 
of oral omeprazole on the median total direct medical cost was examined on a 
range of oral omeprazole price range of $1 to $ 10 per omeprazole 20mg 
capsule. The median total direct medical cost in the diclofenac plus omeprazole 
arm would be the same or lower than the celecoxib group when the cost of oral 
omeprazole was $3 or less (Figure 3). 
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Figure 3 One-way sensitivity analysis of the expected median direct cost of 
the celecoxib group and the diclofenac plus omeprazole group 
using various cost of omeprazole (20mg) 
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3.2.2 Large randomized clinical trial 
3.2.2.1 Demographic data 
The mean ages of the refecoxib group and the naproxen group were 5 8土9 
years and 58+10 years respectively. Three thousand two hundred and twenty 
three (79.6%) patients in the refecoxib group and 3215 (79.8%) patients in the 
naproxen group were female. Three thousand three hundred and twenty one 
(82.1%) patients in the refecoxib group and 3331 (82.7%) patients in the 
naproxen group prior use NSAIDs. 
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3.2.2.2 Cost analysis 
In chapter 2, the U C H data reported a total cost of $12.4 million H K D for 
treating 385 GI events. This gives a mean of approximate $32,200 H K D per 
event. In V I G O R trial, 125 patients treated for 1 year with rofecoxib in order to 
prevent 1 complicated upper GI event. From table 10, the cost of celecoxib was 
$3 H K D more than diclofenac per day, $3 H K D times 365 days equals $1,095 
H K D per year. For a cohort of 125 patients, it would cost $136,875 more H K D 
to provide celecoxib compared with diclofenac in order to prevent one event at a 
cost of $32,200 H K D . 
3.3 Discussion 
3.3.1 Cost analysis 
The main objective of this study was to conduct a cost analysis of 
celecoxib versus diclofenac for patients with arthritis using incidence of GI 
events from (a) local randomized clinical trial and (b) large randomized clinical 
trial. The results of this analysis reported that the total direct medical cost per 
patient and the direct medical cost in the celecoxib group during routine 
management were significantly lower than in the diclofenac plus omperazole 
group in local randomized clinical trial. O n the other hand, for patients who 
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experienced recurrent ulcer bleeding, the direct medical cost utilized to manage 
the bleeding was found to be significantly higher in the celecoxib group. 
Patients with a history of ulcer bleeding are at high risk for developing recurrent 
complications while receiving N S A I D therapy. COX-2 was developed to 
provide anti-inflammatory efficacy comparable to non-selective NSAIDs with 
decrease GI toxicity. It is true that reduced risk and improved tolerability of 
these newer agents. The results in this study are comparable to those observed in 
other cost effectiveness analysis comparing non-selective NSAIDs with or 
without CO prescription of gastroprotective agents. Zabinski et al 2001 
compared the cost and clinical consequence of selective COX-2 inhibitor with 
non-selective NSAIDs with gastroprotective agents, the model indicated that the 
use of selective COX-2 inhibitor could lead to the avoidance of the incremental 
cost of using selective COX-2 inhibitor. Laine et al 2003 have studied the 
gastrointestinal healthcare resources utilization with selective COX-2 inhibitors 
versus non-selective NSAIDs and concluded that patients switching from 
non-selective NSAIDs to selective COX-2 had a slight decrease in the 
proportion using Gl-related resources. In Hong Kong, a cost analysis to 
compare the direct medical cost of selective COX-2 inhibitor versus 
non-selective NSAIDs with or without gastroprotective agents, the model 
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indicated that the use of selective COX-2 inhibitor was appeared to be the least 
costly alternative for intermediate to high GI risk patients [You et al 2002； • 
Laine et al 2003 and Goldstein et al 1997 have demonstrated that a reduction in 
health care resources utilization of COX-2 compared to non-selective NSAIDs. 
Our finding is hence in agreement with the results when all of the health care 
resource utilized for routine management and management of recurrent bleeding 
were considered. 
The median total direct medical cost of routine management of celecoxib 
group was significant lower. This may be explained by an observed lower rate 
of symptom driven resource, such as clinic visits, O G D and laboratory tests, 
utilized in this arm during routine follow up. This demonstrates the reduced 
adverse GI events of selective COX-2 inhibitor on the cost. Besides, results in 
this study showed a higher cost in management of ulcer bleeding in the 
celecoxib group. This may be explained by an observed higher rate of symptom 
driven medical services to which associated with higher management cost. 
Potential explanation for celecoxib failure to show a decrease in GI resource 
utilized including patient characteristics such as baseline co-morbidity. However, 
only a total of 15 patients had experienced recurrent ulcer bleeding, six in 
celecoxib and nine in diclofenac plus omeprazole group. Small number of 
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subjects makes the difference in cost for the management of recurrent ulcer 
bleeding inconclusive. The lower range of the costs estimates of the total direct 
medical cost and cost for routine management of celecoxib and diclofenac plus 
omeprazole group equal to the median. This may be explained by a low rate of 
resources used by most of the patients in both arms. 
O n the other hand, the cost in preventing a GI event with selective COX-2 
was higher than with non-selective N S A I D using the incidence from V I G O R 
trial. Several potential explanations for the failure of selective COX-2 inhibitors 
to decrease cost of preventing a GI event in this evaluation may be postulated, 
including patient baseline co-morbidity. Altaian et al 2000 reported that 
advanced age, patient taking aspirin would increase the risk of GI complications, 
and hence the cost of treating a GI event. However, the study population 
involved in the two trials was widely heterogeneous. The local trial was on 
patients with history of GI bleeding, whereas in the V I G O R trial, only 8 % of 
patients had history of GI events. This might explain the difference in cost was 
observed by using different approaches. Besides, only drug cost was included in 
the analysis of the V I G O R trial. Other GI resources such as clinic follow up, 
hospitalization; GI procedures, A & E visits; O G D and diagnostic test were not 
included in the analysis. Laine et al 2003 concluded that cost were significantly 
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less with non-selective NSAIDs than selective COX-2 when only drug cost 
were included in the analysis. However, when all GI resources used were 
calculated, the cost were decreased when patients switching from non-selective 
NSAIDs to selective COX-2. 
3.3.2 Sensitivity analysis 
Generic omeprazole 20mg are recently available in Hong Kong. It is 
reasonable to examine the effect of generic omeprazole on the effect of the total 
cost since omeprazole 20mg is one of the cost-driver in medication. The 
acquisition cost of generic omeprazole is between $2.3-6.8. Sensitivity analysis 
was performed to acknowledge that each estimate is likely to vary in clinical 
practice. In fact, sensitivity analysis showed that when the drug acquisition cost 
of omeprazole 20mg per tablet is decreased by nearly 7 0 % to around $3, the 
non-selective N S A I D plus omeprazole group would dominate selective COX-2 
strategy. 
3.3.3 Low dose aspirin on NSAID-induced GI toxicity 
Besides, the local clinical trial allowed the use of low dose aspirin for 
cardiovascular prophylaxis and aspirin use was not allowed in large randomized 
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trial, V I G O R . It is documented that the use of concurrent aspirin would increase 
the risk of GI complications. It is possible that the cost of NSAID-induced GI 
events may have been overestimated because some patients were using aspirin 
that could have increased the occurrence of GI adverse events. 
3.3.4 Limitation 
Analyses of this nature are subject to a variety of limitations. Inconsistence 
in reporting styles between the studies analyzed necessitated some assumption 
to be imputed regarding the data. Assumptions has been made that celecoxib is 
as effective as rofecoxib and V I G O R data event rates was used instead of 
C L A S S since celecoxib showed no difference in 12 month event rates compared 
to placebo in the C L A S S trial. Heterogeneity of the recruited study populations 
is another area of potential bias between the trials analyzed with respect to 
preexisting risk factors for GI complication. Besides, the local trial was on 
patients with O A , R A and other forms of arthritis and only R A patients in the 
V I G O R trial. Aspirin was allowed in the local trial but not in V I G O R . Moreover, 
all patients in the local trial had history of GI bleed and only 8 % of patients in 
the V I G O R had a history of GI events. Furthermore, only medication was 
included in the analysis of V I G O R trial. Other GI resources such as clinic 
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follow up, hospitalization; GI procedures, A & E visits; O G D and diagnostic test 
were not included in the analysis. The data collected for this analysis as a result 
of retrospective local clinical trial for Chinese patients at risk for ulcer bleeding. 
This is the only published double blind clinical study to address the safety issue 
of selective COX-2 and non-selective NSAIDs to represent a Hong Kong 
perspective. In a study by Cox et al 2003 on the verification of a decision model 
assumption using clinical practice data suggested that in U S perspective, the 
rate ofGPAuse is slightly higher among COX-2 users than among non-
selective NSAIDs users in clinical practice. In this local study, G P A w a s not 
used among patients in the COX-2 arm. Although the results from local clinical 
trial with detailed protocol that govern the care of enrolled patients may not 
reflect all events happened in clinical practice, this study protocol had been 
designed to simulate standard clinical practice. Most of the diagnostic 
procedures and investigations were symptom driven rather than protocol driven. 
Finally, only the cost need to treat to prevent a serious GI event was calculated 
and the cost of treating a thrombotic event was not included. 
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3.4 Future Study 
Large randomized local clinical trial is needed to better examine the cost 
effectiveness of selective COX-2 inhibitors and non-selective N S A I D for 
treatment as well as prevention of NSAID-induced GI gastropathy could be 
done to broaden the perspective of the use of selective COX-2 inhibitors on 
patients who are at low risk and high risk of ulcer complications. 
3.5 Conclusion 
This local randomized clinical study showed the median total direct 
medical cost of the celecoxib group was lower than that of diclofenac plus 
omeprazole arm for the treatment of arthritis with patients at high risk of 
gastrointestinal bleeding. The finding is hence in agreement with the results of 
the prediction study by decision models. Whereas, the cost in preventing a GI 
event with selective COX-2 was higher than with non-selective N S A I D using 
the incidence from the V I G O R trial which was among general R A patients. 
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Chapter 4 Conclusion 
A considerable amount of money is spent to protect against or manage 
upper GI events associated with NSAIDs. The cost analysis of the local trial 
suggested that the recent recommendation to adopt selective COX-2 inhibitor as 
first line agent and appropriate patient risk management might be potential 
means of reducing NSAID-related health care resources used on high risk 
patients with history of GI bleeding but not on general R A patients in V I G O R 
trial. Cox et al 2003 conducted a study on the cost effectiveness of prescribing 
COX-2 for patients new to COX-2 therapy and concluded that there is no 
evidence to suggest that COX-2 inhibitors are cost effective in the short term 
treatment of pain. 
Selective COX-2 inhibitors are a therapeutic option in the treatment of 
arthritis, which remains debilitating and painful condition. To use selective 
COX-2 inhibitors wisely, physicians need to weigh the risks of improved GI 
safety versus potential cardiovascular risks. Although the cardiovascular risks of 
selective COX-2 inhibitors are now more clearly documented, they have not 
been adequately evaluated in long-term studies in low-risk or high-risk 
populations. In facing the rapidly changing data on selective COX-2 inhibitors 
and the perceived benefit-to-hazard ratio of COX-2 treatment, non-selective 
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NSAIDs plus gastroprotective agents seems to be the first line for musculosketal 
pain, particularly when chronic therapy is anticipated. Patients who are 
sixty-five years or older, have a history of gastric ulcer and not at high risk for 
cardiovascular disease could be benefit from selective COX-2 inhibitors. For 
patients with a history of GI bleeding or concomitantly taking low-dose aspirin 
for cardiovascular prophylaxis, selective COX-2 inhibitors plus a proton pump 
inhibitor may be a choice [Chan 2005]. If a selective COX-2 inhibitor was 
necessary, the lowest possible dose should be used for the shortest possible time. 
W e are all at some risk. The higher the risk, the more willing one is to put 
somebody on a preventive agent that might have some risk associated with it. 
The withdrawal of rofecoxib and valdecoxib alarms physicians and policy 
makers. Celecoxib is the most heavily studied selective COX-2 inhibitor 
available in the market. However, there is bound to be more scrutiny of this 
drug in the months to come. 
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Appendix Data collection form 
HEALTHCARE RESOURCES UTILIZATION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY 
DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS 
OBSERVATION PERIOD: 1/1/99-31/3/99 
A. Patient Details 
Patient name. _________ _ 
I.D. No.: ________ D.O.B.: _______ Sex: M / F Age: __ _ 
Smoker? 0 Y 0 N Alcohol? 0 Y 0 N Known Drug Allergy: ____ _ 
Patient History and Diagnosis 
Exclusion Criteria: 
Type of GI Complication: • Esophageal varices or 
strictures 
0 Gastritis 
• GI malignancies 
0 Duodenitis 
• Coagulopathies 
• Recent Hx. Of alcoholism 
• Cirrhosis 0 Gastric ulcer 
0 Duodenal ulcer 
0 GI hemorrhage 
0 GI Perforation 
Non-steroidal Anti-inflammatory Drugs CNSAIDs) Usage: Within a month prior to GI events 
Name of drug Dose/ Dosing frequency From to 
Hospital ization : 
Admission date Discharge date Discharge diagnosis 
Clinic Follow-up For GI disorders : 
Clinic date Clinic Diagnosis 
75 
Patient No. Page # 
S U R G E R Y / P R O C E D U R E 
Date Type of Surgery/Procedure  
76 
Patient No. Page # 
MEDICATION  
Date Medication Regimen and supply days 
) 
77 
Patient No. Page # 
LABORATORY I DIAGNOSTIC TESTS 
Quantity 
O G D  
C L O test for H P 
Histology for HP 





Total Bilirubin  
Albumin  
Globulin  






C P K  
C K M B  
Amylase  






R B C  
Hgb  
Hot  
M C V  
M C H  
M C H C  
R D W  
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Platelet  
M P V  
PT (11-13)sec  
APTT (20-30)sec  
INR  
pH (7.35-7.45) 
pC〇2 (35-45)mmHg  
p〇2 (80-100)mmHg 
BE  
H C 0 3  
02 Saturation  
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